Imprimir
Imprimir
Email
Email
Aumentar fuente de texto
Aumentar fuente de texto
Reducir fuente de texto
Reducir fuente de texto
Bajar
Ir al fondo de la página
Volver
Volver a la página anterior
» 2016

24 de Junio de 2016

Estimados Miembros de la AAOC

Esta sección del Newsletter es una iniciativa que reafirma nuestro mayor interés: la Educación Médica Continua.

“Lecturas Sugeridas” brinda una selección de trabajos científicos relevantes destinada a la actualización de los profesionales.

Hoy presentamos el trabajo de KR Bosse y JM Maris: Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations” artículo “open access”

Cancer. 2016 Jan 1;122(1):20-33. doi: 10.1002/cncr.29706. Epub 2015 Nov 5.

Bosse KR1,2, Maris JM1,2.

Author information

· 1Division of Oncology and Center for Childhood Cancer Research, Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania.

· 2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Abstract

Neuroblastoma is an embryonal malignancy that commonly affects young children and is remarkably heterogenous in its malignant potential. Recently, the genetic basis of neuroblastoma has come into focus and not only has catalyzed a more comprehensive understanding of neuroblastoma tumorigenesis but also has revealed novel oncogenic vulnerabilities that are being therapeutically leveraged. Neuroblastoma is a model pediatric solid tumor in its use of recurrent genomic alterations, such as high-level MYCN (v-myc avian myelocytomatosis viral oncogene neuroblastoma-derived homolog) amplification, for risk stratification. Given the relative paucity of recurrent, activating, somatic point mutations or gene fusions in primary neuroblastoma tumors studied at initial diagnosis, innovative treatment approaches beyond small molecules targeting mutated or dysregulated kinases will be required moving forward to achieve noticeable improvements in overall patient survival. However, the clonally acquired, oncogenic aberrations in relapsed neuroblastomas are currently being defined and may offer an opportunity to improve patient outcomes with molecularly targeted therapy directed toward aberrantly regulated pathways in relapsed disease. This review summarizes the current state of knowledge about neuroblastoma genetics and genomics, highlighting the improved prognostication and potential therapeutic opportunities that have arisen from recent advances in understanding germline predisposition, recurrent segmental chromosomal alterations, somatic point mutations and translocations, and clonal evolution in relapsed neuroblastoma.

© 2015 American Cancer Society

http://onlinelibrary.wiley.com/doi/10.1002/cncr.29706/pdf

Imprimir
Imprimir
Email
Email
Aumentar fuente de texto
Aumentar fuente de texto
Reducir fuente de texto
Reducir fuente de texto
Subir
Ir a la cabecera de la página
Volver
Volver a la página anterior
© 2010-2017 AAOC. Todos los derechos reservados | Política de Privacidad
Website Developed by 72studio